Related Experiment Video

Updated: Aug 7, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment

F H Bouwman1, S N M Schoonenboom, W M van der Flier

  • 1Department of Neurology, Alzheimer Centre, VU Medical Center, MB Amsterdam, The Netherlands. femke.bouwman@vumc.nl <femke.bouwman@vumc.nl>

Neurobiology of Aging
|June 20, 2006
PubMed
Abstract

Insights

Predicting dementia in mild cognitive impairment (MCI) patients is improved by combining cerebrospinal fluid (CSF) biomarkers, like beta-amyloid(1-42) and tau, with medial temporal lobe atrophy (MTA) MRI scans.

Area of Science:

  • Neurology
  • Biomarkers
  • Neuroimaging

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Identifying individuals with MCI who will progress to dementia is crucial for timely intervention.
  • Current diagnostic methods may lack sufficient predictive power for dementia conversion.

Purpose of the Study:

  • To evaluate the predictive value of cerebrospinal fluid (CSF) biomarkers beta-amyloid(1-42) (Abeta(1-42)) and tau for dementia development in MCI patients.
  • To assess the role of medial temporal lobe atrophy (MTA) on MRI in predicting dementia progression in MCI.
  • To determine the combined predictive accuracy of CSF biomarkers and MTA for dementia conversion.

Main Methods:

  • A cohort of 59 MCI patients (mean age 69±8 years) was followed for 19 months.
  • Baseline CSF levels of Abeta(1-42) and tau, along with MTA scores from MRI, were dichotomized.
  • Cox proportional hazards models were used to analyze the association between baseline measures and dementia conversion.

Main Results:

  • 56% of MCI patients progressed to dementia, most commonly Alzheimer's disease.
  • Lower CSF Abeta(1-42), higher CSF tau, and higher MTA scores were associated with dementia progression.
  • Abnormal CSF Abeta(1-42), CSF tau, and MTA significantly predicted dementia (HRs: 4.0, 5.9, 2.1 respectively).
  • Patients with both abnormal CSF biomarkers and MTA had a fourfold higher risk of dementia and 94% conversion rate.

Conclusions:

  • CSF biomarkers (Abeta(1-42), tau) and MTA on MRI are significant predictors of dementia in MCI patients.
  • Combining CSF biomarkers with MTA enhances the prediction of dementia conversion.
  • These findings support the integrated use of CSF analysis and MRI in memory clinics for improved diagnostic workup.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...